Creating, facilitating and promoting sustainable Health Technology Assessment (HTA) cooperation in Europe
Creating, facilitating and promoting sustainable Health Technology Assessment (HTA) cooperation in Europe
Publication of EUnetHTA 21 deliverable ”JCA without HTD submission”
EUnetHTA 21 is pleased to announce the publication of the EUnetHTA 21 deliverable ”JCA without HTD submission”. We thank everyone involved for their work on
The EUnetHTA 21 Consortium will cease operations on 16 September 2023
The European Health and Digital Executive Agency (HADEA) signed the Service Contract for the Provision of Joint Health Technology Assessment (HTA) Work Supporting the Continuation
EUnetHTA 21 response to ARM article
In 2022 the EUnetHTA 21 Consortium worked together to produce a number of guidelineswhich outline the methods that are used to undertake Joint Clinical Assessments
Publication of the EUnetHTA 21 – EMA work plan
EUnetHTA 21 is pleased to announce the publication of the EUnetHTA 21 – EMA work plan. EMA and EUnetHTA 21 work closely together, to prepare for
Publication of second Joint Clinical Assessment
The EUnetHTA 21 is pleased to announce the publication of their second Joint Clinical Assessment. One of the objective of the JCA production was to
Parallel EMA/HTA body (HTAb) Scientific Advice during Interim Period post EUnetHTA 21
The Parallel EMA/EUnetHTA 21 Joint Scientific Consultations (JSCs) under the EUnetHTA 21 service contract will have to be completed by September 2023 and all available
COVID-19 Response
EUnetHTA has prioritised COVID-19-related initiatives above other work during the current time. Here you will find updated information and publications relating to COVID-19 diagnostic testing, therapeutic treatments, and useful links to further data from our network partners.
Services
EUnetHTA develops several services that help inform the decision-making process around the introduction of pharmaceuticals and other technologies at the national, regional, and European levels. These include Joint Assessments, Early Dialogues, and Post Launch Evidence Generation (PLEG). Find out more here.
Assessments
Pharmaceutical Joint Assessments (PTJA) and Other Technologies Collaborative Assessments (OTCA) are key EUnetHTA outputs. Find current project status, EUnetHTA Prioritisation List (EPL) and Topic Identification, Selection, and Prioritisation (TISP), uptake data and archived content here.
Tools
EUnetHTA has developed a suite of tools to complement all steps in the collaborative joint work process, helping partners to proceed with a defined methodology. Access all current and archived tools here.
Get Involved
EUnetHTA functions as a collaboration between network members and exterior partners to develop joint work. These include patients, industry, regulators, HCPs, and payers. Find out more about partner involvement, activities, and EUnetHTA events here.
COVID-19 Response
EUnetHTA has prioritised COVID-19-related initiatives above other work during the current
time. Here you will find updated information and publications relating to COVID-19 diagnostic
testing, therapeutic treatments, and useful links to further data from our network partners.
Services
EUnetHTA develops several services that help inform the decision-making process around the
introduction of pharmaceuticals and other technologies at the national, regional, and
European levels. These include Joint Assessments, Early Dialogues, and Post Launch Evidence
Generation (PLEG). Find out more here.
Assessments
Pharmaceutical Joint Assessments (PTJA) and Other Technologies Collaborative Assessments
(OTCA) are key EUnetHTA outputs. Find current project status, EUnetHTA Prioritisation List
(EPL) and Topic Identification, Selection, and Prioritisation (TISP), uptake data and archived
content here.
Tools
EUnetHTA has developed a suite of tools to complement all steps in the collaborative joint
work process, helping partners to proceed with a defined methodology. Access all current and
archived tools here.
Get Involved
EUnetHTA functions as a collaboration between network members and exterior partners to
develop joint work. These include patients, industry, regulators, HCPs, and payers. Find out
more about partner involvement, activities, and EUnetHTA events here.
